MARKET

PLXP

PLXP

PLx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.85
+0.17
+1.57%
Opening 10:00 04/23 EDT
OPEN
10.70
PREV CLOSE
10.68
HIGH
10.95
LOW
10.62
VOLUME
5.97K
TURNOVER
--
52 WEEK HIGH
10.97
52 WEEK LOW
2.310
MARKET CAP
247.73M
P/E (TTM)
-6.4963
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22)
Benzinga · 2h ago
New Analyst Coverage Puts Spotlight on These 4 Stocks
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Guess' (GES), Babcock (BW), Wabash (WNC) and PLx Pharma (PLXP).
Zacks · 1d ago
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14)
Benzinga · 04/15 11:49
Provention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst action
The FDA feedback on an upcoming regulatory review and differing opinions on commercialization prospects of key therapies are some of the reasons for analysts to change their outlook on stocks
Seekingalpha · 04/09 13:11
DJ PLx Pharma Initiated at Outperform by Oppenheimer
Dow Jones · 04/09 12:06
DJ PLx Pharma Price Target Announced at $20.00/Share by Oppenheimer
Dow Jones · 04/09 12:06
PLx Pharma (PLXP) Initiated with a Buy at Oppenheimer
PLx Pharma (PLXP) received a Buy rating and a $20.00 price target from Oppenheimer analyst Leland Gershell today. The company's shares closed last
SmarterAnalyst · 04/09 10:22
The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 17)
Benzinga · 03/18 12:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLXP. Analyze the recent business situations of PLx Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLXP stock price target is 16.00 with a high estimate of 20.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 21
Institutional Holdings: 2.12M
% Owned: 9.29%
Shares Outstanding: 22.84M
TypeInstitutionsShares
Increased
2
61.60K
New
3
67.44K
Decreased
3
28.78K
Sold Out
2
34.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.15%
Pharmaceuticals & Medical Research
+0.31%
Key Executives
Chief Financial Officer
Rita O'Connor
Chief Financial Officer
Rita O Connor
Chief Accounting Officer/Treasurer
Robert Shawah
Vice President/Director of Sales
Steven Valentino
Vice President
Tom Long
Director
Gary Balkema
Director
Tony Bartsh
Director
Anthony Bartsh
Director
Kirk Calhoun
Director
Robert Casale
Director
Natasha Giordano
Director
John Hadden
Director
Michael Valentino
No Data
About PLXP
PLx Pharma Inc. is a late-stage specialty pharmaceutical company. It is focusing on developing clinically-validated and patent-protected PLxGuard delivery system. Its lead product, Vazalore 325 mg, which is a formulation of aspirin using the PLxGuard delivery system intended to provide antiplatelet for cardiovascular disease prevention as compared to the current standard of care, enteric-coated aspirin, and significantly reduce gastric side effects. The Company has also developed Vazalore 81 mg, a lower-dose companion product for Vazalore 325 mg. The PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system that may be developed, including a clinical-stage, GI-safer ibuprofen, PL1200 Ibuprofen 200 mg, for pain and inflammation.

Webull offers kinds of PLx Pharma Inc stock information, including NASDAQ:PLXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLXP stock methods without spending real money on the virtual paper trading platform.